Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
Status:
Active, not recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if sorafenib (sorafenib tosylate) is a safe and
effective treatment option for preventing liver cancer in high risk patients following liver
transplantation. Liver transplantation is a treatment option for liver cancer patients, but
despite transplantation, the liver cancer can recur in the new, transplanted liver. It is not
known whether sorafenib is effective in preventing cancer recurrence in high risk patients
following liver transplantation